Recovery · Reference
TB-500 Benefits: What the Research Actually Shows
This page goes benefit by benefit: what was studied, in what, whether it used TB-500 or the full protein, and how much weight it can bear, then side effects, FDA status and how Pepti supplies it. For the full reference on the molecule, see what is TB-500.
Treatments mentioned
The benefits described for TB-500 come from animal and cell research on thymosin beta-4, the 43-amino-acid protein TB-500 is a fragment of: faster skin wound closure in rats and mice, repair cells migrating into injured tissue, new blood vessel growth, and heart and corneal repair in mice. Full-length thymosin beta-4 has small human trials as eye drops for dry eye and as a topical treatment for skin ulcers, but TB-500 itself, the seven-amino-acid fragment that is injected, has no human trials for any use. The only study to test TB-500 by name in a tendon was a 2026 rat study. Every benefit below is something research describes, not something a vial can promise.
This page goes benefit by benefit: what was studied, in what, whether it used TB-500 or the full protein, and how much weight it can bear, then side effects, FDA status and how Pepti supplies it. For the full reference on the molecule, see what is TB-500.
TB-500 Benefits
The short answer
| Claimed benefit | What the evidence is | Strength of evidence |
|---|---|---|
| Repair cells moving into injured tissue | Cell (human endothelial cells in culture) and reviews | The best-described mechanism; not measured in people |
| Skin wound healing | Animal (rats, diabetic and aged mice, including the fragment); human (small phase 2 trials of the full protein, topical) | Consistent in animals; human data is the full protein on the skin, not the injected fragment |
| New blood vessel growth | Animal (mouse wound and heart models) | Animal only |
| Heart repair after injury | Animal (mouse heart attack models) | Strong preclinical work; no human trial of TB-500 |
| Eye and cornea healing | Animal and cell; human (phase 2 trial of full-protein eye drops) | The strongest human data, but eye drops of a different molecule |
| Calming inflammatory signaling | Cell and animal eye (NF-kB pathway) | Preliminary |
| Less scarring, matrix remodeling | Cell and animal (laminin-5, matrix metalloproteinases) | Preliminary |
| Tendon, ligament and muscle repair | Animal (one 2026 rat Achilles study) | The thinnest area, and the one most people ask about |
| Hair growth | Animal and cell (full protein in rat and mouse follicles) | Animal only; no human trial |
| Flexibility, joint comfort | No studies | Not studied |
Flexibility and joint-comfort claims appear in marketing, but no study has measured them, and nothing in the research describes a painkilling mechanism. The pattern is clear: a broad animal literature, almost all on the full protein, and no human data on the fragment that is prescribed. Pepti supplies TB-500 as a 5 mL vial at 1 mg/mL (5 mg per vial) for $209/mo, all-in, and in several blends listed further down.
TB-500 Benefits
What TB-500 is, briefly
Thymosin beta-4 is one of the most abundant small proteins inside human cells, where it holds actin, the protein that lets a cell move, in reserve. Platelets release it at injury sites.
TB-500 is a synthetic seven-amino-acid fragment of that protein, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (LKKTETQ, positions 17 to 23), the region that binds actin. That distinction decides how to read every section below. Most published work, and every human trial, used the full 43-amino-acid protein. That the fragment does what the parent does is a reasonable inference from the shared sequence, and a few animal studies support it, but it has not been tested in people. The FDA's July 2026 briefing put it directly: "thymosin beta-4 and TB-500 are not the same substance."
TB-500 Benefits
Benefit by benefit
1. Repair cells moving into injured tissue
What the research describes. This is the foundational mechanism and the one most directly tied to the fragment, because the actin-binding region is what TB-500 is. A 1997 paper in the FASEB Journal reported thymosin beta-4 stimulating directional migration of human endothelial cells in culture. A 2005 review in Trends in Molecular Medicine describes the protein "moonlighting": a housekeeping actin buffer that, once released after injury, also acts as a signal drawing repair cells into the wound. A 2010 paper in the FASEB Journal mapped which of the protein's activities short sequences could reproduce.
What it does not show. These are cell studies. Nobody has measured repair-cell migration in a person given TB-500. A 2024 study in the Journal of Chromatography B found that, at the single concentration tested, TB-500 itself did not close an in-vitro fibroblast wound, while one of its shorter breakdown products did; the FDA cited this as showing it is unknown whether TB-500 acts directly or through a metabolite.
2. Skin wound healing
What the research describes. The original and best-developed area. A 1999 paper in the Journal of Investigative Dermatology reported that thymosin beta-4, applied to the skin or given by intraperitoneal injection, sped up closure of full-thickness skin wounds in rats, with more collagen and new blood vessels than saline. A 2003 paper in Wound Repair and Regeneration extended that to diabetic and aged mice, both models of impaired healing, and tested the LKKTETQ fragment alongside the full protein, reporting that it promoted repair comparably. That paper is the closest published bridge to TB-500.
In people, a 2012 paper in the Annals of the New York Academy of Sciences summarized phase 2 trials of a topical thymosin beta-4 gel in pressure ulcers, venous stasis ulcers and epidermolysis bullosa, reporting faster closure in some dose groups than placebo.
What it does not show. The human trials used the full protein as a gel on the wound, not the fragment by injection, and none was a large phase 3.
3. New blood vessel growth
What the research describes. Endothelial cells build blood vessels, so an effect on their migration leads naturally to angiogenesis. A 2004 paper in Mechanisms of Ageing and Development reported thymosin beta-4 promoting angiogenesis and wound repair in mice. The logic for soft tissue is that tendons and ligaments have a poor blood supply, and blood supply often limits how fast they recover.
What it does not show. It is animal work. The same mechanism is the main caution: a tumor needs a blood supply too, which is why a cancer history matters (covered below).
4. Heart repair after injury
What the research describes. A 2004 paper in Nature reported thymosin beta-4 activating integrin-linked kinase and the Akt survival pathway in heart cells, with treated mice recovering more heart function after an induced heart attack. A 2007 paper in Nature described it mobilizing adult epicardial progenitor cells and driving new vessel growth in the mouse heart, and a 2023 paper in Cardiovascular Research reported cardiac regeneration after ischemic injury in mice.
What it does not show. These are mouse findings. TB-500 is not a treatment for any heart condition, and no human cardiac trial of the fragment exists.
5. Eye and cornea healing
What the research describes. A 2002 paper in Experimental Eye Research reported thymosin beta-4 promoting corneal healing and reducing inflammation after chemical injury in mice, and a 2002 paper in Current Eye Research reported it promoting migration of human conjunctival cells in culture. This line produced the strongest human data in the whole literature: a 2015 phase 2 randomized, placebo-controlled trial in Cornea gave thymosin beta-4 eye drops to people with severe dry eye and described improvement in signs and symptoms versus placebo. A 2010 report in Archives of Ophthalmology described a small series in non-healing corneal defects.
What it does not show. Eye drops of the full protein in an eye condition. It says nothing about an injected fragment for anything else.
6. Calming inflammatory signaling
What the research describes. A corneal research group describes thymosin beta-4 suppressing NF-kB, the transcription factor that switches on many inflammatory genes: in corneal cells in a 2007 paper in Experimental Eye Research, and against TNF-alpha-driven activation in a 2011 paper in the FASEB Journal.
What it does not show. It is a described pathway in cells and animal eyes, not a demonstrated anti-inflammatory effect in a human joint or tendon. If systemic inflammation is the concern, KPV is usually the conversation; see KPV benefits.
7. Less scarring and matrix remodeling
What the research describes. Wound closure needs cells to lay down and then reorganize the matrix around them. A 2004 paper in Experimental Cell Research reported thymosin beta-4 stimulating production of laminin-5, a protein that anchors skin cells to the tissue beneath, and a 2006 paper in the Journal of Cellular Physiology described it promoting matrix metalloproteinase expression during wound repair.
What it does not show. No human study has measured scarring on TB-500.
8. Tendon, ligament and muscle repair
What the research describes. A 2026 paper in Joint Diseases and Related Surgery randomized 32 rats with a repaired Achilles tendon to control, BPC-157, TB-500 or both for four weeks. Load to failure was higher in both peptide groups than in controls, reaching statistical significance for TB-500, and the combination did no better than either peptide alone. It is one of very few animal experiments to use the fragment itself, and the first direct evidence that TB-500 does something measurable in a tendon model.
What it does not show. It is one exploratory rat study, eight animals per group, with intraperitoneal rather than subcutaneous dosing, a four-week endpoint and no dose-ranging. Before it, the tendon case was an inference from the skin and heart work rather than a body of tendon studies. There are no human studies of TB-500 for any tendon, ligament or muscle injury. More on this use is in peptides for tendon and ligament injuries.
9. Hair growth
What the research describes. A 2004 paper in the FASEB Journal reported that thymosin beta-4 increased hair growth in normal rats and mice and acted on follicle stem cells in the bulge region, promoting their migration and differentiation. A 2007 paper in the Annals of the New York Academy of Sciences extended this across several rodent models.
What it does not show. That work used the full protein. There is no human hair trial of thymosin beta-4 or TB-500. See peptides for hair growth.
TB-500 Benefits
The human studies, all of them
The FDA searched PubMed, Embase and ClinicalTrials.gov in 2026 and found no clinical study or human exposure data for TB-500 by any route. All of the human studies below used full-length thymosin beta-4.
| Year | Design | Route | People | What was reported |
|---|---|---|---|---|
| 2010 | Randomized, placebo-controlled single and multiple dose | Intravenous | Healthy volunteers | Well tolerated, no dose-limiting adverse events |
| 2010 | Small case series | Eye drops | Non-healing corneal defects | Described in Archives of Ophthalmology |
| 2012 | Phase 2 trials | Topical gel | Pressure ulcers, venous stasis ulcers, epidermolysis bullosa | Faster closure in some dose groups than placebo |
| 2015 | Phase 2 randomized, placebo-controlled | Eye drops | Severe dry eye | Improvement in signs and symptoms versus placebo |
None used the TB-500 fragment, none used subcutaneous injection, and none looked at a tendon, muscle or joint. Any source citing "human trials of TB-500" for injury recovery is borrowing evidence from a different molecule, route and condition.
TB-500 Benefits
What the evidence shows, honestly
The thymosin beta-4 animal literature is broad, spanning skin, cornea, heart and hair, its actin-binding mechanism is solid biology, and the parent protein has been through a small clinical program. That is the case for TB-500, and why it is prescribed.
It is not the same as evidence that TB-500 works in people. The fragment has no human data, its own animal record is a handful of studies, and one cell assay raises the question of whether the fragment acts directly at all. The accurate framing is "described in preclinical research, with human trials of the parent protein in unrelated conditions, and used clinically on that basis." For tendinopathy, progressive loading under a physical therapist has human trial evidence that TB-500 does not, so it is reasonable to do that first or alongside. A complete rupture or displaced fracture is a surgical question no peptide changes. A provider promising a healing timeline is inventing it.
TB-500 Benefits
Side effects, in summary
TB-500 is reported as well tolerated, but that rests on animal studies and prescriber experience rather than on human safety trials of the fragment. The full safety picture is in is TB-500 safe.
| How often | What is reported | What to do |
|---|---|---|
| Common | Injection-site redness, itching, a small lump, tenderness | Rotate sites; mention it at follow-up |
| Common | Tiredness or a head-fog feeling in the first one to two weeks | Report it; it usually settles |
| Uncommon | Light-headedness or a flushed feeling shortly after dosing | Report it to your care team |
| Uncommon | Transient joint or muscle ache | Report it |
| Stop and call | A site that is hot, spreading or worsening after 48 hours; any new lump, unexplained bleeding | Stop dosing and contact your physician the same day |
| Stop and get help | Facial or throat swelling, widespread rash, breathing difficulty | Emergency care first (call 911), then tell your physician |
The specific cautions are active or recent cancer (thymosin beta-4 is a protein many tumors express, and its described mechanisms overlap with the ones tumors use), pregnancy or breastfeeding (no developmental or reproductive studies exist), blood thinners, autoimmune disease, and an injury that has not been imaged. The FDA's central stated concern is immunogenicity, an immune reaction to aggregated peptide or impurities, which is an argument for a tested pharmacy preparation. TB-500 is prohibited at all times under S2.3 of the 2026 WADA Prohibited List as a thymosin beta-4 derivative, so tested athletes should tell their physician before starting.
TB-500 Benefits
Where TB-500 stands with the FDA
TB-500 was placed in Category 2 of the FDA's 503A bulk substances list in 2023, over potential immunogenicity. In April 2026 the FDA removed it from Category 2 along with eleven other peptides. On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding TB-500 to the 503A Bulks List, against the FDA staff's proposal; the FDA's final determination is pending. It remains legal to prescribe and dispense as a compounded medication. Compounded medications, TB-500 included, are not FDA approved.
TB-500 Benefits
How Pepti supplies it
| Product | What is in it | Typical directions | Price |
|---|---|---|---|
| TB-500 | 5 mL vial, 1 mg/mL (5 mg TB-500) | 0.25 mL (25 units) subcutaneously Monday through Friday mornings, 0.25 mg per dose, 20 doses | $209/mo |
| BPC-157 + TB-500 | 5 mg BPC-157 and 5 mg TB-500 in 5 mL | 0.25 mL (25 units) Monday through Friday mornings | $259/mo |
| GLOW | 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 in 5 mL | 0.25 mL (25 units) Monday through Friday mornings | $259/mo |
| KLOW | 50 mg GHK-Cu, 10 mg KPV, 10 mg BPC-157, 10 mg TB-500 in 5 mL | 0.25 mL (25 units) Monday through Friday mornings | $259/mo |
| ETERNAL | 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, 10 mg Epithalon in 5 mL | 0.25 mL (25 units) once daily Monday through Friday | $279/mo |
| REVIVE | 50 mg GHK-Cu, 6 mg CJC-1295, 12 mg Ipamorelin, 2 mg TB-500 in 5 mL | 0.25 mL (25 units) Monday through Friday nights at bedtime | $279/mo |
Each price is all-in: medication, physician review, refill management and shipping, with no membership fee. Pepti is cash-pay and does not bill insurance. TB-500 on its own is a vial only, with no pen cartridge. Twenty weekday doses is four weeks, so refills run every 28 days, one vial per fill. Vials arrive as a multi-dose solution ready to use, with directions printed on the vial, sterile syringes and alcohol prep pads, shipped refrigerated with ice packs. Lot test results are at /quality/lab-results.
TB-500 is most often paired with BPC-157, a combination known online as the Wolverine stack; the comparison is in BPC-157 vs TB-500. If you were looking for the immune peptide with a similar name, that is a different molecule: see thymosin alpha-1 vs TB-500.
TB-500 Benefits
Where to get TB-500 prescribed
TB-500 cannot be bought legitimately without a prescription. "TB-500" is a common name rather than an official drug name, and the FDA reports encountering multiple salts and derivatives, including different active substances, sold under that one label. The prescription route:
- Complete a free online intake covering your history, medications and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A pharmacy compounds it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with your directions printed on the vial.
- Your physician stays reachable for questions and dose changes.
Pepti prescribes TB-500 in every state except Oklahoma, plus DC Step by step: how to get TB-500 prescribed online and how to get BPC-157 + TB-500 prescribed online. How a prescription vial differs from an online seller is in where to buy TB-500 online.
References
What this is based on.
References
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues · Trends Mol Med (2005) · PMID 16099219
- Malinda KM, Sidhu GS, Mani H et al.. Thymosin beta4 accelerates wound healing · J Invest Dermatol (1999) · PMID 10469335
- Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells · FASEB J (1997) · PMID 9194528
- Philp D, Badamchian M, Scheremeta B et al.. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice · Wound Repair Regen (2003) · PMID 12581423
- Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development · Mech Ageing Dev (2004) · PMID 15037013
- Philp D, Scheremeta B, Sibliss K et al.. Thymosin beta4 promotes matrix metalloproteinase expression during wound repair · J Cell Physiol (2006) · PMID 16607611
- Smart N, Risebro CA, Melville AA et al.. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization · Nature (2007) · PMID 17108969
- Sosne G, Szliter EA, Barrett R et al.. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury · Exp Eye Res (2002) · PMID 11950239
- Sosne G, Hafeez S, Greenberry AL 2nd et al.. Thymosin beta4 promotes human conjunctival epithelial cell migration · Curr Eye Res (2002) · PMID 12324865
- Sosne G, Xu L, Prach L et al.. Thymosin beta 4 stimulates laminin-5 production independent of TGF-beta · Exp Cell Res (2004) · PMID 14729067
- Sosne G, Qiu P, Christopherson PL et al.. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway · Exp Eye Res (2007) · PMID 17254567
- Sosne G, Qiu P, Goldstein AL et al.. Biological activities of thymosin beta4 defined by active sites in short peptide sequences · FASEB J (2010) · PMID 20179146
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
TB-500 Benefits, answered.
The benefits described in research are repair cells migrating into injured tissue, faster skin wound closure, new blood vessel growth, heart and corneal repair, and hair growth, almost all in rats, mice and cells, and almost all using full-length thymosin beta-4. TB-500 itself has no human trials.
No. The FDA found no human study of TB-500 by any route. Full-length thymosin beta-4 has small phase 2 trials as eye drops for dry eye and as a gel for skin ulcers, which are a different molecule, route and condition.
Its research is broadest for skin wound healing and cell migration, and it is most often prescribed for soft-tissue recovery, usually alongside BPC-157. That use rests on animal research and one 2026 rat tendon study.
In one 2026 rat study of a repaired Achilles tendon, TB-500 was associated with higher load to failure than control. No human trial has tested it, so nobody can tell you whether or how much faster a given injury might recover.
No. Thymosin beta-4 is the full 43-amino-acid protein your cells make; TB-500 is a synthetic seven-amino-acid fragment built around its actin-binding region. Most of the research cited for TB-500 used the full protein.
They are described in different parts of repair and are usually prescribed together rather than instead of each other. BPC-157 has the deeper tendon-specific animal literature; TB-500's parent protein has the deeper skin, eye and heart literature. See BPC-157 vs TB-500.
There is no timeline from human trials, because none have been run. Any timeline you see is prescriber experience, not a measured result. A vial covers four weeks at the standard directions.
Mostly injection-site redness, itching or a small lump, and sometimes tiredness in the first week or two or a brief flushed or light-headed feeling. Facial or throat swelling, a widespread rash or difficulty breathing is an emergency.
Anyone with an active or recent cancer, anyone pregnant or breastfeeding, and tested athletes (it is prohibited at all times). People on blood thinners or with autoimmune disease should discuss it with their physician first.
No. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.